2. resources & tools
  3. faqs

Frequently Asked Questions

Have questions about NAROPIN? Get them answered below.

  • What concentrations of NAROPIN are available?
  • The following concentrations of NAROPIN are available:
    • 2 mg/mL (0.2%)
    • 5 mg/mL (0.5%)
    • 7.5 mg/mL (0.75%)
    • 10 mg/mL (1%)
  • Solutions of NAROPIN are available in a range of dosage forms:
    • Single Dose Vials
    • Single Dose Sterile-Pak Vial
    • Plastic Ampule Sterile-Pak
    • freeflex bag
    • Infusion Bottles
  • What are the recommended concentrations, doses, and infusion rates of NAROPIN for its indicated uses?
  • What are common (≥5%) side effects reported when using NAROPIN?
  • Like all amide-type anesthetics, NAROPIN may be associated with adverse reactions. In clinical trials, side effects were mild and transient and may have reflected the procedures, patient health status, and/or other medications used. Adverse events reported at a rate of ≥5%: hypotension, nausea, vomiting, bradycardia, fever, pain, postoperative complications, anemia, paresthesia, headache, pruritus, and back pain.1
  • What are the differences between NAROPIN and bupivacaine?
  • NAROPIN offers faster return of motor function with effective onset and duration of sensory block.2,3 See clinical information
  • What is freeflex®?
  • freeflex is an innovative bag designed for infusion solutions that Fresenius Kabi has marketed globally since 2005. The bag is made from multilayer polyolefin film that is non-PVC and non-DEHP and is designed to help provide the pharmacy and clinicians greater confidence in critical therapies. Its clear labeling, innovative technology, and enhanced port design provide a simplified user experience.
  • What is the difference between NAROPIN freeflex bag and infusion bottle?
  • While both presentations are ready to use and have the same indication, premix bags like freeflex have advantages to help simplify user experience:
    • Easy to stack and store
    • Eliminates glass and incurs
      less breakage
    • Does not require vented
      sets, helping to reduce the
      risk of extrinsic contamination4,5
    • Additive port gives flexibility to
      customize patient therapy
  • What are Plastic Ampule Sterile-Paks?
  • Plastic Ampule Sterile-Paks are polypropylene ampules that are designed for needle-free draw-up, offering protection from glass shards, needles, and latex. Plastic Ampule Sterile-Paks are compatible with Luer-lock and Luer-slip (tapered syringes). Each Plastic Ampule is individually sterilized in its outer packaging to enable use in the sterile field.

References

1. NAROPIN Prescribing Information. 2. Knudsen K, Beckman SM, Blomberg S, Sjövall J, Edvardsson N. Central nervous and cardiovascular effects of iv infusions of ropivacaine, bupivacaine and placebo in volunteers. Br J Anaesth. 1997;78:507-514. 3. Scott DB, Lee A, Fagan D, Bowler GMR, Bloomfield P, Lundh R. Acute toxicity of ropivacaine compared with that of bupivacaine. Anesth Analg. 1989;69:563-569. 4. Maki DG, Rosenthal VD, Salomao R, Franzetti F, Rangel-Frausto MS. Impact of switching from an open to a closed infusion system on rates of central line–associated bloodstream infection: a meta-analysis of time-sequence cohort studies in 4 countries. Infect Control Hosp Epidemiol. 2011;32:50-58. 5. Rangel-Frausto MS, Higuera-Ramirez F, Martinez-Soto J, Rosenthal VD. Should we use closed or open infusion containers for prevention of bloodstream infections? Ann Clin Microbiol Antimicrob. 2010;9:6.

Important Safety Information

Using NAROPIN beyond recommended doses to increase motor block or duration of sensory block may negate its favorable cardiovascular advantages, in the event that an inadvertent intravascular injection occurs. NAROPIN may be associated with adverse reactions which are characteristic of those associated with other amide-type local anesthetics.1 In clinical trials, side effects were mild and transient and may reflect the procedures, patient health status, and/or other medications used. Adverse events reported at a rate of ≥5%: hypotension, nausea, vomiting, bradycardia, fever, pain, postoperative complications, anemia, paresthesia, headache, pruritus, and back pain.

There have been adverse event reports of chondrolysis in patients receiving intra-articular infusions of local anesthetics following arthroscopic and other surgical procedures. NAROPIN is not approved for this use.

Please see Full Prescribing Information.

1. NAROPIN Prescribing Information Data on file.

NAROPIN is indicated for the production of local or regional anesthesia for surgery and acute pain management.

NAROPIN and logo are registered trademarks of Fresenius Kabi USA, LLC. ©2015, Fresenius Kabi USA, LLC. All Rights Reserved.